Stemline Therapeutics Inc (STML)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ivan Bergstein
Employees:
92
750 LEXINGTON AVENUE, ELEVENTH FLOOR, NEW YORK, NY 10022
646-502-2311

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Data derived from most recent annual or quarterly report
Market Cap 595.937 Million Shares Outstanding50.375 Million Avg 30-day Volume 1.99 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.55
Price to Revenue5.4028 Debt to Equity0.0 EBITDA-73.129 Million
Price to Book Value1.7214 Operating Margin-155.51489999999998 Enterprise Value102.629 Million
Current Ratio7.429 EPS Growth0.488 Quick Ratio7.18
1 Yr BETA 1.0509 52-week High/Low 0.0 / Profit Margin-150.3021
Operating Cash Flow Growth23.1859 Altman Z-Score3.3518 Free Cash Flow to Firm -62.793 Million
View SEC Filings from STML instead.

View recent insider trading info

Funds Holding STML (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding STML

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-06-10:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-03-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-08-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-08-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-04-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-01-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-12-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ZUERBLIS KENNETH J

    • Director
    No longer subject to file 2020-06-10 0

    BENTSUR RON

    • Director
    No longer subject to file 2020-06-10 0

    FORMAN ALAN S

    • Director
    No longer subject to file 2020-06-10 0

    GIONCO DAVID CHIEF ACCOUNTING OFFICER

    • Officer
    No longer subject to file 2020-06-10 0

    BERGSTEIN IVAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    No longer subject to file 2020-06-10 0

    HOBERMAN KENNETH CHIEF OPERATING OFFICER

    • Officer
    No longer subject to file 2020-06-10 0

    CLINE DARREN S

    • Director
    No longer subject to file 2020-06-10 0

    HUME DANIEL

    • Director
    No longer subject to file 2020-06-10 0

    SARD MARK

    • Director
    No longer subject to file 2020-06-10 0

    FRANCOMANO ROBERT CHIEF COMMERCIAL OFFICER

    • Officer
    No longer subject to file 2020-06-10 0

    BERGSTEIN IVAN CHIEF EXECUTIVE OFFICER

    BERGSTEIN IVAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    2,726,151 2019-02-25 0

    DOBMEIER ERIC

    • Director
    27,963 2017-06-19 0

    BUCHI J KEVIN

    • Director
    23,772 2015-06-23 0

    ROWINSKY ERIC K CHIEF MEDICAL OFFICER

    • Officer
    143,688 2015-04-27 0

    HALL STEPHEN P CHIEF ACCOUNTING OFFICER

    • Officer
    40,000 2013-06-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments